Clinical trial NCT02394054: Vasopressin and the Social Brain
Official title: Vasopressin's Effect on Behavior and Neural Activity During Social Cognition Tasks
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Social Psychology
Keywords: vasopressin
intranasal administration
healthy sample
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
First posted: 2015-03-20
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: It has long been established that interpersonal relationships can have a profound impact on health and well-being. Yet, the investigators are still learning about the complex biological processes that contribute to positive social interactions and the ability to develop and maintain social relationships. Recent research has begun to focus on vasopressin, a neuropeptide that is naturally produced in the hypothalamus, because administration of this neuropeptide has been associated with empathy, cooperation, memory of social stimuli (e.g., faces), and brain activity in neural regions associated with social and emotional processes. To date, several aspects of vasopressin's effects on social behavior have been unexplored. As such, the overarching goal of this project is to examine the effects of intranasal vasopressin on several tasks involving learning and social processes. In addition, the investigators will explore associated neural activity through functional magnetic resonance imaging (fMRI). Results from the study will inform our understanding of the neurobiology of socioemotional processes.

The investigators hypothesize that compared to placebo, vasopressin will improve deception detection, increase empathy and altruism, enhance responses to photo stimuli of primary caregivers, and improve learning when the subject has a prosocial goal of teaching another person. These effects will manifest in behavioral and neural activity. It is also hypothesized that main effects will not be found for vasopressin, but rather, analyses of relevant moderators will elucidate these findings.


Eligibility criteria: Inclusion Criteria:

* 18-30 years of age
* Healthy (see below)
* Fluent in English
* Right-handed

Exclusion Criteria:

* Women who gave birth in the last six months, are currently pregnant, planning to become pregnant in the next 6 months, or currently breastfeeding women
* Symptoms of runny nose due to allergies/cold or other reason
* Current restricted fluid intake for any reason
* Heart disease
* Hypertension
* History of myocardial infarction
* History of cardiac arrhythmia
* Kidney or liver disease
* Vascular disease
* Epilepsy
* Migraine
* Asthma
* Nephritis
* Diabetes and other endocrine diseases
* Frequent or unexplained fainting
* History of stroke
* Aneurysm or brain hemorrhage
* Active psychiatric diagnosis
* Current psychopharmacologic treatment
* Drug or alcohol abuse
* Medical or neurological illness
* Regular use of medication (e.g., vasoconstrictive medications)
* Medication intake less than 2 weeks prior to study (5 weeks for fluoxetine) including daily non-steroidal anti-inflammatory drugs
* Smoking more than 15 cigarettes a day
* Consumption of any alcoholic beverages in the past 24 hours will be excluded
* Elevated blood pressure (\>135/90)
* Low blood pressure (\<90/55)
* Body temperature \>100.1 F
* Left-handed
* Claustrophobia
* Presence of metal in their body

Primary outcomes:
measure: Changes in neural brain activity, as observed by fMRI, when observing others during social inclusion vs. exclusion
timeFrame: Between 40-115 minutes post administration
Secondary outcomes:
measure: Ratings of empathic concern after witnessing social exclusion in a friend or a stranger
timeFrame: Between 40-115 minutes post administration
measure: Altruism and punishment as measured by number of points given to excluders and those excluded
timeFrame: Between 40-115 minutes post administration
measure: Changes in neural brain activity, as observed by fMRI, while attempting to detect deception
timeFrame: Between 40-115 minutes post administration
measure: Accuracy of deception detection as measured by self-report
timeFrame: Between 40-115 minutes post administration
measure: Changes in neural brain activity, as observed by fMRI, when viewing images of primary caregivers versus strangers
timeFrame: Between 40-115 minutes post administration
measure: Changes in brain neural activity, observed by fMRI, in response to a reading comprehension task
timeFrame: Between 40-90 minutes post administration
measure: Performance on a memory test of reading comprehension as measured by percentage of questions answered correctly
timeFrame: Between 40-90 minutes post administration
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA Department of Psychology
state: California
Study officials:
affiliation: University of California, Los Angeles
name: Matthew D Lieberman, PhD
role: PRINCIPAL_INVESTIGATOR
References: